vs

Side-by-side financial comparison of CHOICEONE FINANCIAL SERVICES INC (COFS) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

CHOICEONE FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($42.9M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 76.4%). CHOICEONE FINANCIAL SERVICES INC produced more free cash flow last quarter ($25.2M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 15.0%).

ChoiceOne Financial Services Inc is a US regional financial holding company that operates through its banking subsidiary, offering personal and commercial banking products including savings accounts, loans, wealth management, and insurance services primarily to consumers, small businesses, and corporate clients across Michigan.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

COFS vs RXRX — Head-to-Head

Bigger by revenue
COFS
COFS
1.2× larger
COFS
$42.9M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+605.4% gap
RXRX
681.7%
76.4%
COFS
More free cash flow
COFS
COFS
$72.5M more FCF
COFS
$25.2M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
15.0%
COFS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
COFS
COFS
RXRX
RXRX
Revenue
$42.9M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
39.1%
-304.8%
Net Margin
-304.2%
Revenue YoY
76.4%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$1.43
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COFS
COFS
RXRX
RXRX
Q4 25
$42.9M
$35.5M
Q3 25
$61.8M
$5.2M
Q2 25
$60.4M
$19.2M
Q1 25
$44.9M
$14.7M
Q4 24
$24.3M
$4.5M
Q3 24
$36.6M
$26.1M
Q2 24
$34.0M
$14.4M
Q1 24
$32.5M
$13.8M
Net Profit
COFS
COFS
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$14.7M
$-162.3M
Q2 25
$13.5M
$-171.9M
Q1 25
$-13.9M
$-202.5M
Q4 24
$-178.9M
Q3 24
$7.3M
$-95.8M
Q2 24
$6.6M
$-97.5M
Q1 24
$5.6M
$-91.4M
Gross Margin
COFS
COFS
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
COFS
COFS
RXRX
RXRX
Q4 25
39.1%
-304.8%
Q3 25
29.6%
-3327.6%
Q2 25
27.6%
-916.8%
Q1 25
-39.2%
-1297.9%
Q4 24
36.1%
-4042.4%
Q3 24
25.4%
-377.1%
Q2 24
24.0%
-697.4%
Q1 24
21.1%
-698.4%
Net Margin
COFS
COFS
RXRX
RXRX
Q4 25
-304.2%
Q3 25
23.7%
-3135.3%
Q2 25
22.4%
-894.2%
Q1 25
-31.0%
-1373.3%
Q4 24
-3935.5%
Q3 24
20.1%
-367.5%
Q2 24
19.4%
-676.6%
Q1 24
17.3%
-662.4%
EPS (diluted)
COFS
COFS
RXRX
RXRX
Q4 25
$1.43
$-0.17
Q3 25
$0.97
$-0.36
Q2 25
$0.90
$-0.41
Q1 25
$-1.29
$-0.50
Q4 24
$0.79
$-0.56
Q3 24
$0.85
$-0.34
Q2 24
$0.87
$-0.40
Q1 24
$0.74
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COFS
COFS
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$88.0M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$465.4M
$1.1B
Total Assets
$4.4B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COFS
COFS
RXRX
RXRX
Q4 25
$88.0M
$743.3M
Q3 25
$99.0M
$659.8M
Q2 25
$156.3M
$525.1M
Q1 25
$139.4M
$500.5M
Q4 24
$96.8M
$594.4M
Q3 24
$145.9M
$427.6M
Q2 24
$101.0M
$474.3M
Q1 24
$150.1M
$296.3M
Total Debt
COFS
COFS
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
COFS
COFS
RXRX
RXRX
Q4 25
$465.4M
$1.1B
Q3 25
$449.6M
$1.0B
Q2 25
$431.8M
$919.1M
Q1 25
$427.1M
$933.9M
Q4 24
$260.4M
$1.0B
Q3 24
$247.7M
$524.6M
Q2 24
$214.5M
$584.4M
Q1 24
$206.8M
$401.2M
Total Assets
COFS
COFS
RXRX
RXRX
Q4 25
$4.4B
$1.5B
Q3 25
$4.3B
$1.4B
Q2 25
$4.3B
$1.3B
Q1 25
$4.3B
$1.3B
Q4 24
$2.7B
$1.4B
Q3 24
$2.7B
$726.5M
Q2 24
$2.7B
$775.9M
Q1 24
$2.7B
$557.8M
Debt / Equity
COFS
COFS
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COFS
COFS
RXRX
RXRX
Operating Cash FlowLast quarter
$31.8M
$-46.1M
Free Cash FlowOCF − Capex
$25.2M
$-47.3M
FCF MarginFCF / Revenue
58.7%
-133.1%
Capex IntensityCapex / Revenue
15.4%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$38.5M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COFS
COFS
RXRX
RXRX
Q4 25
$31.8M
$-46.1M
Q3 25
$15.3M
$-117.4M
Q2 25
$9.0M
$-76.4M
Q1 25
$-6.5M
$-132.0M
Q4 24
$47.1M
$-115.4M
Q3 24
$-7.4M
$-59.2M
Q2 24
$15.7M
$-82.2M
Q1 24
$15.3M
$-102.3M
Free Cash Flow
COFS
COFS
RXRX
RXRX
Q4 25
$25.2M
$-47.3M
Q3 25
$13.7M
$-117.6M
Q2 25
$6.9M
$-79.6M
Q1 25
$-7.3M
$-133.8M
Q4 24
$45.4M
$-116.7M
Q3 24
$-7.6M
$-63.8M
Q2 24
$15.3M
$-83.4M
Q1 24
$15.0M
$-109.0M
FCF Margin
COFS
COFS
RXRX
RXRX
Q4 25
58.7%
-133.1%
Q3 25
22.1%
-2272.5%
Q2 25
11.4%
-413.9%
Q1 25
-16.3%
-907.4%
Q4 24
186.4%
-2567.7%
Q3 24
-20.8%
-244.6%
Q2 24
44.8%
-578.5%
Q1 24
46.2%
-789.9%
Capex Intensity
COFS
COFS
RXRX
RXRX
Q4 25
15.4%
3.5%
Q3 25
2.6%
4.7%
Q2 25
3.4%
16.4%
Q1 25
1.9%
12.4%
Q4 24
7.0%
28.6%
Q3 24
0.7%
17.5%
Q2 24
1.4%
8.2%
Q1 24
1.0%
48.2%
Cash Conversion
COFS
COFS
RXRX
RXRX
Q4 25
Q3 25
1.04×
Q2 25
0.66×
Q1 25
Q4 24
Q3 24
-1.00×
Q2 24
2.39×
Q1 24
2.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons